Stemtech Reports 47.4% Revenue Decline in Q2 2025, Despite Reduced Net Loss

Stemtech Corporation has reported its financial results for the second quarter of 2025, revealing a significant decline in revenue compared to the same period last year. For the three months ending June 30, 2025, the company generated net sales of $697,925, a decrease of 47.4% from $1,325,800 in the prior year. The six-month figures also reflect a downturn, with sales dropping to $1,565,971 from $2,708,370. Despite the revenue decline, the company reported a reduced net loss of $296,280 for the quarter, down from $784,087 in the same quarter of 2024, and a six-month net loss of $1,755,006 compared to $2,204,716 in the previous year.

The company's cost of goods sold (COGS) also saw a notable reduction, amounting to $145,909 for the second quarter, down from $332,177 in 2024. This improvement in COGS, which reflects a positive variance of $186,268, is attributed to enhanced operational efficiencies and cost management strategies. Operating expenses decreased significantly as well, totaling $853,004 for the quarter, a reduction of 49.5% from $1,685,932 in the prior year. This decrease is largely due to strategic cuts in commissions and marketing expenses, aligning with the company's focus on long-term growth rather than short-term volume.

In terms of operational developments, Stemtech has been actively restructuring its business model to enhance distributor quality and sustainability. The company aims to add 30,000 new Independent Business Partners (IBPs) over the next 12 to 24 months, which is expected to bolster product distribution and reduce customer acquisition costs. Additionally, Stemtech has launched new products, including Cellect One® Shield HOCL and StemPets™, and is developing a Direct-to-Consumer marketing strategy to expand its reach without the need for upfront inventory purchases.

As of June 30, 2025, Stemtech's total assets stood at $3,872,156, an increase from $3,782,245 at the end of 2024. However, the company's liabilities also rose to $10,323,863 from $9,009,049, primarily due to increased accounts payable and accrued expenses. The company reported a working capital deficiency of approximately $6.4 million, raising concerns about its ability to continue as a going concern. Management has outlined plans to address liquidity needs, including potential capital raises of $5-7 million through private placements and a convertible debt facility of up to $3 million.

Looking ahead, Stemtech is optimistic about its long-term growth prospects, particularly as awareness of stem cell benefits continues to rise. The company anticipates that its strategic initiatives, including improved customer engagement and operational efficiencies, will lead to a more sustainable revenue stream. Management projects that revenue could increase by 15-20% in the upcoming quarters as new products are launched and the distributor base expands. However, the company acknowledges the need for additional capital to support its growth plans and operational requirements.